Catal­ent ex­pands in­hala­tion ef­forts in col­lab­o­ra­tion with Texas-based phar­ma

TFF Phar­ma­ceu­ti­cals is on the hunt for new part­ners, and a re­cent­ly-an­nounced agree­ment with Catal­ent could help them land just that.

The two com­pa­nies an­nounced a col­lab­o­ra­tion fo­cused on the gen­er­a­tion, test­ing and man­u­fac­ture of dry pow­der for­mu­la­tions Tues­day.

Thin film freez­ing is a plat­form tech­nol­o­gy that works on both small and large mol­e­cules. The process con­verts mol­e­cules in­to an in­haled dry pow­der, which de­liv­ers the drug di­rect­ly to the lungs. That’s an “out­stand­ing” or­gan for drug dis­tri­b­u­tion me­tab­o­lism, CEO Glenn Mattes said on a call with End­points News. The com­pa­ny is al­so work­ing on oral, in­traoc­u­lar and top­i­cal for­mu­la­tions. The ad­van­tage would be a low­er amount of drug in­ter­ac­tion, and a bet­ter side ef­fect pro­file, he said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER